Invivyd logo_
Invivyd Elects Two New Independent Members to its Board of Directors
22 mai 2024 07h00 HE | Invivyd
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced...
Invivyd logo_
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
13 mai 2024 16h01 HE | Invivyd
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced...
Invivyd logo_
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
09 mai 2024 16h01 HE | Invivyd
Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune compromiseReported interim exploratory COVID-19 clinical...
Invivyd logo_
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
07 mai 2024 07h30 HE | Invivyd
Pathway leverages immunobridging approach via serum virus neutralizing antibody (sVNA) titers enabled by prior successful COVID-19 treatment clinical trial “STAMP” conducted with prototype antibody...
Invivyd logo_
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
02 mai 2024 17h13 HE | Invivyd
WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced...
Invivyd logo_
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
30 avr. 2024 07h30 HE | Invivyd
Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel monoclonal antibodiesCompany now expects...
Invivyd logo_
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
15 avr. 2024 07h30 HE | Invivyd
Invivyd Receives HCPCS Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) covering PEMGARDA
Invivyd logo_
Invivyd Announces CEO Transition
12 avr. 2024 07h30 HE | Invivyd
WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today...
invivyd-logo.jpg
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
04 avr. 2024 16h01 HE | Invivyd
PEMGARDA now commercially available in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Based on anticipated net...
invivyd-logo.jpg
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
28 mars 2024 07h00 HE | Invivyd
Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with...